> top > docs > PubMed:26253900 > annotations

PubMed:26253900 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 7-12 PR:Q5S006 denotes LRRK2
T2 7-12 PR:000003033 denotes LRRK2
T3 7-12 PR:Q5S007 denotes LRRK2
T4 17-22 GO:0007568 denotes aging
T5 30-44 D004198 denotes susceptibility
T6 30-44 D004198 denotes susceptibility
T8 48-58 GO:0000502 denotes proteasome
T7 48-58 GO:0004299 denotes proteasome
T9 48-68 D061988 denotes proteasome inhibitor
T10 48-68 D061988 denotes proteasome inhibitor
T11 48-68 CHEBI:52726 denotes proteasome inhibitor
T13 108-127 UBERON:0027239 denotes dopaminergic system
T15 133-140 6308 denotes leucine
T16 133-140 SO:0001437 denotes leucine
T14 133-140 CHEBI:15603 denotes leucine
T17 133-140 D007930 denotes leucine
T18 133-140 CHEBI:25017 denotes leucine
T19 133-140 D007930 denotes leucine
T20 146-152 SO:0001068 denotes repeat
T21 163-168 PR:Q5S006 denotes LRRK2
T22 163-168 PR:000003033 denotes LRRK2
T23 163-168 PR:Q5S007 denotes LRRK2
T24 170-178 SO:0000109 denotes mutation
T29 230-249 D010300 denotes Parkinson's disease
T30 230-249 D010300 denotes Parkinson's disease
T33 281-286 PR:Q5S006 denotes LRRK2
T34 281-286 PR:000003033 denotes LRRK2
T35 281-286 PR:Q5S007 denotes LRRK2
T36 376-382 CHEBI:27026 denotes toxins
T37 387-392 GO:0007568 denotes aging
T38 420-425 PR:Q5S006 denotes LRRK2
T39 420-425 PR:000003033 denotes LRRK2
T40 420-425 PR:Q5S007 denotes LRRK2
T41 437-449 GO:0009405 denotes pathogenesis
T42 523-527 PR:000005054 denotes mice
T44 523-527 O89094 denotes mice
T43 523-527 D051379 denotes mice
T45 523-527 10095 denotes mice
T46 543-548 PR:Q5S006 denotes LRRK2
T47 543-548 PR:000003033 denotes LRRK2
T48 543-548 PR:Q5S007 denotes LRRK2
T49 549-557 SO:0000109 denotes mutation
T50 559-562 SO:0000153 denotes BAC
T51 570-575 PR:Q5S006 denotes LRRK2
T52 570-575 PR:000003033 denotes LRRK2
T53 570-575 PR:Q5S007 denotes LRRK2
T54 576-586 SO:0000781 denotes transgenic
T55 592-596 PR:000005054 denotes mice
T57 592-596 O89094 denotes mice
T56 592-596 D051379 denotes mice
T58 592-596 10095 denotes mice
T59 651-662 CHEBI:52722 denotes lactacystin
T60 651-662 C067713 denotes lactacystin
T61 651-662 C067713 denotes lactacystin
T63 675-685 GO:0000502 denotes proteasome
T62 675-685 GO:0004299 denotes proteasome
T64 675-695 D061988 denotes proteasome inhibitor
T65 675-695 D061988 denotes proteasome inhibitor
T66 675-695 CHEBI:52726 denotes proteasome inhibitor
T68 701-717 D004198 denotes susceptibilities
T69 701-717 D004198 denotes susceptibilities
T70 721-725 PR:000005054 denotes mice
T72 721-725 O89094 denotes mice
T71 721-725 D051379 denotes mice
T73 721-725 10095 denotes mice
T74 729-740 CHEBI:52722 denotes lactacystin
T75 729-740 C067713 denotes lactacystin
T76 729-740 C067713 denotes lactacystin
T81 856-867 CHEBI:52722 denotes lactacystin
T82 856-867 C067713 denotes lactacystin
T83 856-867 C067713 denotes lactacystin
T84 936-940 PR:000005054 denotes mice
T86 936-940 O89094 denotes mice
T85 936-940 D051379 denotes mice
T87 936-940 10095 denotes mice
T88 1026-1037 CHEBI:52722 denotes lactacystin
T89 1026-1037 C067713 denotes lactacystin
T90 1026-1037 C067713 denotes lactacystin
T91 1055-1059 PR:000005054 denotes mice
T93 1055-1059 O89094 denotes mice
T92 1055-1059 D051379 denotes mice
T94 1055-1059 10095 denotes mice
T100 1102-1110 SO:0001446 denotes tyrosine
T96 1102-1110 10962 denotes tyrosine
T103 1102-1122 A0A060X6Z0 denotes tyrosine hydroxylase
T102 1102-1122 D014446 denotes tyrosine hydroxylase
T104 1154-1158 PR:000005054 denotes mice
T106 1154-1158 O89094 denotes mice
T105 1154-1158 D051379 denotes mice
T107 1154-1158 10095 denotes mice
T112 1271-1282 CHEBI:52722 denotes lactacystin
T113 1271-1282 C067713 denotes lactacystin
T114 1271-1282 C067713 denotes lactacystin
T115 1314-1333 CL:0002629 denotes activated microglia
T117 1337-1353 UBERON:0002038 denotes substantia nigra
T118 1357-1361 PR:000005054 denotes mice
T120 1357-1361 O89094 denotes mice
T119 1357-1361 D051379 denotes mice
T121 1357-1361 10095 denotes mice
T122 1397-1401 PR:000005054 denotes mice
T124 1397-1401 O89094 denotes mice
T123 1397-1401 D051379 denotes mice
T125 1397-1401 10095 denotes mice
T130 1483-1491 SO:0000109 denotes mutation
T131 1499-1504 10090 denotes mouse
T132 1499-1504 D051379 denotes mouse
T133 1505-1510 PR:Q5S006 denotes LRRK2
T134 1505-1510 PR:000003033 denotes LRRK2
T135 1505-1510 PR:Q5S007 denotes LRRK2
T136 1511-1515 SO:0000704 denotes gene
T137 1547-1561 D004198 denotes susceptibility
T138 1547-1561 D004198 denotes susceptibility
T140 1565-1575 GO:0000502 denotes proteasome
T139 1565-1575 GO:0004299 denotes proteasome

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-6 REPLACED denotes G2019S
T2 7-12 Token_Label.OUTSIDE denotes LRRK2
T3 13-128 DRI_Background denotes and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
T4 129-255 DRI_Approach denotes The leucine-rich repeat kinase 2 (LRRK2) mutation G2019S is one of the most common genetic causes in Parkinson's disease (PD).
T5 256-273 DRI_Challenge denotes The penetrance of
T6 274-286 Token_Label.OUTSIDE denotes G2019S LRRK2
T7 287-412 DRI_Challenge denotes is incomplete and is age-dependent, therefore, it has been speculated that environmental toxins and aging could contribute to
T8 413-433 Token_Label.OUTSIDE denotes G2019S LRRK2-related
T9 434-450 DRI_Challenge denotes PD pathogenesis.
T10 451-535 DRI_Approach denotes To prove this speculation, we performed a longitudinal investigation in mice bearing
T11 536-548 Token_Label.OUTSIDE denotes G2019S LRRK2
T12 549-558 DRI_Approach denotes mutation.
T13 559-562 DRI_Background denotes BAC
T14 563-575 Token_Label.OUTSIDE denotes G2019S LRRK2
T15 576-696 DRI_Background denotes transgenic (Tg) mice and their wildtype (Wt) littermates were treated with lactacystin, a specific proteasome inhibitor.
T16 697-728 DRI_Background denotes The susceptibilities of mice to
T17 729-762 Token_Label.OUTSIDE denotes lactacystin-induced nigrostriatal
T18 763-841 DRI_Background denotes dopaminergic (DAergic) degeneration were evaluated, at 5 and 12 months of age.
T19 842-1011 DRI_Outcome denotes We found that lactacystin treatment caused a greater decline of striatal DA content in the Tg mice at either 5 or 12 months of age than their age-matched Wt littermates.
T20 1012-1192 DRI_Background denotes Moreover, the lactacystin-treated Tg or Wt mice at 12 months of age lose much more nigral tyrosine hydroxylase (TH)-positive neurons than the mice at 5 months of age, indicating an
T21 1193-1215 Token_Label.OUTSIDE denotes age-associated DAergic
T22 1216-1230 DRI_Background denotes neurotoxicity.
T23 1231-1421 DRI_Background denotes Additionally, stereotactic injection of lactacystin induced a dramatic increase of activated microglia in substantia nigra of mice at 12 months of age, compared with mice at 5 months of age.
T24 1422-1575 DRI_Outcome denotes In summary, our study suggests that expression of the G2019S mutation in the mouse LRRK2 gene confers an age-associated high susceptibility to proteasome
T25 1576-1616 Token_Label.OUTSIDE denotes inhibition-induced nigrostriatal DAergic
T26 1617-1630 DRI_Outcome denotes degeneration.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 129-255 DRI_Approach denotes The leucine-rich repeat kinase 2 (LRRK2) mutation G2019S is one of the most common genetic causes in Parkinson's disease (PD).
T2 256-273 DRI_Challenge denotes The penetrance of
T3 287-412 DRI_Challenge denotes is incomplete and is age-dependent, therefore, it has been speculated that environmental toxins and aging could contribute to
T4 434-450 DRI_Challenge denotes PD pathogenesis.
T5 451-535 DRI_Approach denotes To prove this speculation, we performed a longitudinal investigation in mice bearing
T6 549-558 DRI_Approach denotes mutation.
T7 559-562 DRI_Background denotes BAC
T8 576-696 DRI_Background denotes transgenic (Tg) mice and their wildtype (Wt) littermates were treated with lactacystin, a specific proteasome inhibitor.
T9 697-728 DRI_Background denotes The susceptibilities of mice to
T10 763-841 DRI_Background denotes dopaminergic (DAergic) degeneration were evaluated, at 5 and 12 months of age.
T11 842-1011 DRI_Outcome denotes We found that lactacystin treatment caused a greater decline of striatal DA content in the Tg mice at either 5 or 12 months of age than their age-matched Wt littermates.
T12 1012-1192 DRI_Background denotes Moreover, the lactacystin-treated Tg or Wt mice at 12 months of age lose much more nigral tyrosine hydroxylase (TH)-positive neurons than the mice at 5 months of age, indicating an
T13 1216-1230 DRI_Background denotes neurotoxicity.
T14 1231-1421 DRI_Background denotes Additionally, stereotactic injection of lactacystin induced a dramatic increase of activated microglia in substantia nigra of mice at 12 months of age, compared with mice at 5 months of age.
T15 1422-1575 DRI_Outcome denotes In summary, our study suggests that expression of the G2019S mutation in the mouse LRRK2 gene confers an age-associated high susceptibility to proteasome
T16 1617-1630 DRI_Outcome denotes degeneration.